Connect with us

BUSINESS

Cara Therapeutics Inc (NASDAQ:CARA) Will Report Topline Data Of Pivotal KALM-2 Phase 3 Trial Of KORSUVA Injection In Q2 2020: Will Submit NDA For KORSUVA Injection To FDA

Published

on

Cara Therapeutics Inc (NASDAQ:CARA) is on track to provide topline data for the pivotal KALM-2 Phase 3 clinical trial of KORSUVA injection in Q2 2020. The company is conducting phase 3 clinical trial of KORSUVA injection in hemodialysis patients suffering from CKD-ap. It will also submit NDA (New Drug Application) for KORSUVA injection to the US FDA in Q2.

CEO and President of Cara, Derek Chalmers said under the updated guidance of the FDA the company is on track to report topline data from KALM-2 in Q2 despite the ongoing coronavirus crisis. He further said the company is making significant progress in phase 3 clinical trial of KORSUVA injection that comprises supportive safety data.

Evaluates Oral KORSUVA for atopic dermatitis

Cara is conducting phase 2 clinical trials on oral KORSUVA for the treatment of atopic dermatitis in patients suffering from moderate to severe pruritus, and patients suffering from hepatic impairment due to PBC (primary biliary cholangitis), and patients with pruritus. The company will conclude an interim statistical analysis in Q2 for the ongoing phase 2 trial in patients with atopic dermatitis. It will present the data from the previous positive phase 2 dose clinical trial of Oral KORSUVA to cure pruritus in patients suffering from moderate to severe CKD at the National Kidney Foundation Spring Clinical Meeting.

KALM-2 phase 3 clinical trial

The placebo-controlled, randomized, multicenter 12-week phase 2 trial evaluates the efficacy and safety of 0.5 mcg/kg KORSUVA injection in four hundred thirty patients suffering from moderate to severe pruritus. In the primary efficacy end-point, a proportion of the patients should at least achieve a three-point improvement in the weekly mean data of the 24‑hour Worst Itching Intensity Numeric Rating Scale daily at the end of week 12.

Cara has reported the topline data from phase 3 KALM-1 US trials in May 2019. It has achieved the primary end-point along with a significant improvement. The trial also accomplished the secondary end-point and the patients have well tolerated the KORSUA injection during a 12-week treatment.

Cara is pleased to announce that Derek will take part in the 19th Annual Needham Healthcare Conference on April 15, 2020. The investors can access web recording from its website.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Trulieve Cannabis Corp (OTCMKTS: TCNNF) Announces a Listening and Education Tour

Published

on

Trulieve Cannabis Corp (OTCMKTS: TCNNF) will host a Listening and Education Tour. The tour aims to meet with local leaders and exchange ideas. It will cover topics like expungement, agricultural, economic, and medical opportunities in the cannabis industry.

Champ Bailey will moderate the event

Champ Bailey, a football Hall of Famer and the chief diversity officer at Trulieve Georgia, will moderate the event. Additionally, Trulieve will hold its first event at the Carolyn Harris Performing Arts Center, Adel.

According to Bailey, a resident and native of Georgia, he is excited to meet experts and teach people the medical benefits of cannabis. He adds that Trulieve will make several tour stops to meet with community leaders. With the help of these leaders, the company will teach locals about how the cannabis industry could change the community. It will also create local support programs.

Experts that will be at the events

Moreover, the programs will have various industry experts, including Jim Wernick, the Director of State Expansion at Trulieve; Dr. James Lillard, the lead researcher at more house school of Medicine; Chase Daughtrey, a Cook County Judge, Heather Green, the president of the Adel-cook County Chamber of Commerce, and Luther Duke, the Mayor of Adel.

Trulieve is asking communities to submit questions before each stop through its emails. After the sessions, the company will also try to develop ways to help the community.

Trulieve is a cannabis company that operates in 11 U.S states. It has leading operations in Pennsylvania, Florida, and Arizona. Its other locations are Maryland, West Virginia, Connecticut, Massachusetts, and California.

Trulieve focuses on logistics, cultivating, processing, manufacturing, wholesale, and retail of cannabis and cannabis-infused products. It sells these products through Trulieve branded retail stores. It also has an online website where customers can purchase its products.

Trulieve products include nasal sprays, tinctures, vapes, edibles, dissolvable powders, capsules, topicals, concentrates, and flowers. It sells them through the Roll One, Modern Flower, Loveli, Co2lors, Avenue, Alchemy, Sweet Talk, Muse, Momenta, and Cultivar Collection brands.

The company also has 161 dispensaries, 112 of which are in Florida. Its headquarters are in Quincy, Florida.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Medical Marijuana Inc’s (OTCMKTS: MJNA) Subsidiary, HempMeds Brasil, Will Sponsor an Obesity Medicine Symposium

Published

on

HempMeds Brasil, a subsidiary of Medical Marijuana Inc (OTCMKTS: MJNA), will sponsor the first Obesity Medicine Symposium for the Brazilian Society of Obesity. This event will take place on March 3-6, 2022.

The symposium will educate people on the benefits of cannabidiol

The Symposium will be at the Centro South Convention Center, Santa Catarina. It aims to bring together medical professionals, wellness organizations, and educators to talk about technological innovations and techniques that have emerged in treating obesity. HempMeds is sponsoring the event to spread awareness on how cannabidiol can be a crucial step in wellness routines.

According to Matheus Patelli, the Managing Director at Hemp Meds Brasil, the event gives the company a chance to educate people on cannabidiol. It will also highlight the benefits of cannabinoids in wellness, how people can use them, and the research surrounding them.

Patelli adds that the event will benefit both the people and the company as cannabidiol is legal in the country. Moreover, the government subsidizes it, so people know how and when to use it.

HempMeds will also give a presentation

Besides providing sponsorship for the event, HempMeds will also give a presentation on cannabidiol and medical cannabis on March 4. The presentation will touch on products in Brazil, their safety, legality, and applications.

Blake Schroeder, the CEO of Medical Marijuana, states that the company has had high revenue and operational growth in the last few years. Furthermore, its brand presence enabled it to host and sponsor the event. Schroeder adds that it has partnered with high-profile researchers and doctors. This move has allowed Medical Marijuana to educate and be transparent with its customers.

HempMeds Brasil was among the first cannabis companies which the National Sanitary Surveillance Agency has approved to import cannabidiol-based products. The company’s license allows it to supply products to various medical centers.

These products treat multiple sclerosis, chronic pain, Parkinson’s disease, and epilepsy. HempMeds is developing products for other diseases.

HempMeds’ parent company, Medical Marijuana, is a cannabis company that operates under various subsidiaries. Other than HempMeds, or also owns Kannaway. The company also partners with companies like Neuropathix and Axim Biotechnology Inc. Its headquarters are in San Diego, California.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Fire & Flower Holdings Corp’s (OTCMKTS: FFLWF) Subsidiary, Pineapple Express Delivery Inc, Will Offer Delivery in Metro Vancouver

Published

on

Pineapple Express Delivery Inc, a subsidiary of Fire & Flower Holdings Corp (OTCMKTS: FFLWF), will offer next business day delivery via e-commerce websites owned by British Columbia Cannabis stores in Metro Vancouver. This will start on February 28, 2022.

Pineapple express makes fast deliveries

Pineapple Express is the most prominent cannabis delivery company. It does over 40,000 deliveries monthly to medical and adult-use cannabis customers in Canada. This company has become an essential part of Fire & Flower holdings since its acquisition on January 25, 2022.

According to the President of Pineapple Express, Randy Rolph, the company recognizes its customers’ need for fast delivery. Cannabis users in the Metro Vancouver area will now take advantage of the subsidiary’s services as it will begin offering next-day delivery services in British Columbia.

Ralph adds that Pineapple Express is very efficient with the fastest and highest scale in the country. The company can also make cost-effective deliveries.

Fire & Flower is a cannabis retailer that has over 100 stores. It uses Hifyre, a technology development subsidiary, to improve its operations and increase revenues. It also educates its customers on cannabis use.

Fire & Flower stores

Fire & Flower sells cannabis products through numerous stores. One of its first stores is Friendly Stranger, which opened in 1994 in Canada. This store has been advocating for cannabis legalization for years.

Friendly Stranger has worked to educate people on the benefits of using cannabis. It has also fought for people who were unfairly charged with cannabis use and made safe hemp products available for the people.

Another store that Fire & Flower owns is Happy Dayz which opened in 2007. The store now has 9 locations in Ontario. Unlike Friendly Stranger, these stores are smaller with an engaging team to give customers a more personalized experience.

HotBox Cannabis is a store that serves customers in Toronto. It also comes with a cannabis consumption lounge at 204 Augusta Street. This lounge, which was the first in Toronto, is near its 206 Augusta store, making it more convenient for cannabis customers. The lounge also sells accessories.

Fire & Flower also uses the Open Field Distribution logo to distribute wholesale products in Saskatchewan.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories